Document ID: chunk:federal_register_of_legislation:F2017L00467:reg:9:p2
Version: federal_register_of_legislation:F2017L00467
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 5859–9098

the clinical onset of bronchiectasis;
Note: specified list of connective tissue diseases is defined in the Schedule 1 - Dictionary.
(16)      being infected with human immunodeficiency virus before the clinical onset of bronchiectasis;
(17)      having a haematological malignancy at the time of the clinical onset of bronchiectasis;
(18)      being treated with an immunosuppressive drug within the five years before the clinical onset of bronchiectasis;
Note: immunosuppressive drug is defined in the Schedule 1 - Dictionary.
(19)      being infected with human T-cell lymphotropic virus type 1 before the clinical onset of bronchiectasis;
(20)      having inflammatory bowel disease at the time of the clinical onset of bronchiectasis;
(21)      having severe and persistent asthma within the five years before the clinical onset of bronchiectasis;
Note: severe and persistent asthma is defined in the Schedule 1 - Dictionary.
(22)      having chronic obstructive pulmonary disease at the time of the clinical onset of bronchiectasis;
(23)      having an episode of acute viral or bacterial lower respiratory tract infection requiring medical treatment, within the one year before the clinical worsening of bronchiectasis;
(24)      having pertussis within the ten years before the clinical worsening of bronchiectasis;
(25)      having pulmonary tuberculosis or non-tuberculous mycobacterial infection of the lung before the clinical worsening of bronchiectasis;
(26)      having sarcoidosis of the lung before the clinical worsening of bronchiectasis;
(27)      having bronchial obstruction before the clinical worsening of bronchiectasis, where the bronchiectasis is distal to that obstruction;
Note: bronchial obstruction is defined in the Schedule 1 - Dictionary.
(28)      inhaling vapours, gases or fumes of a chemical agent from the specified list of chemical agents:
(a)          resulting in signs and symptoms of severe acute lower respiratory damage requiring medical attention within 48 hours after exposure; and
(b)          the persistence of respiratory symptoms and signs for at least one week after exposure,

         within the five years before the clinical worsening of bronchiectasis;

Note: specified list of chemical agents is defined in the Schedule 1 - Dictionary.
(29)      having an occupational lung disease from the specified list of occupational lung diseases at the time of the clinical worsening of bronchiectasis;
Note: specified list of occupational lung diseases is defined in the Schedule 1 - Dictionary.
(30)      inhaling sulphur mustard (mustard gas) before the clinical worsening of bronchiectasis;
(31)      having aspiration pneumonitis within the five years before the clinical worsening of bronchiectasis;
Note: aspiration pneumonitis is defined in the Schedule 1 - Dictionary.
(32)      having gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture, within the two years before the clinical worsening of bronchiectasis;
(33)      having allergic bronchopulmonary aspergillosis at the time of the clinical worsening of bronchiectasis;
Note: allergic bronchopulmonary aspergillosis is defined in the Schedule 1 - Dictionary.
(34)      undergoing solid organ or